Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Radium-223 in Combination with Enzalutamide in Progressive Metastatic Castrate-Resistant Prostate Cancer
2013-004850-97Phase 2Completed
- Sponsor
- Cancer Trials Ireland
- Start
- Nov 2013
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals, Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of radium-223 dichloride and enzalutamide in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Cancer Trials Ireland. Started Nov 2013; status: completed.
02
Drugs
radium-223 dichlorideenzalutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2013-004850-97.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004850-97.